Dr. Claire Pomeroy, Founding Director Emeritus of Expanesthetics and President of the Lasker Foundation, offers important context in the leading Capitol Hill publication as Congress debates funding levels for science and medical research.
The Defense Department and Food and Drug Administration have launched a joint pilot program to prioritize efficiently developing safe and effective medical products to save the lives of U.S. warfighters.
EDITOR'S NOTE: One of Expanesthetics' programs may qualify for this DOD/FDA program, post-pilot.
Dr. Ash Patel discusses three of the biggest macroeconomic trends in healthcare: an aging population, expanding markets in emerging economies worldwide, and the growth of usable medical databases.
EDITOR'S NOTE: Expanesthetics lies at the intersection of two of these trends.
Large biotech companies have been providing lower total shareholder returns (TSR) when compared to smaller biotech companies, and the reason may be that smaller biotech companies are able to focus on a particular category and better understand the needs and value drivers of that category.
Investments in biotech are on the rise with a 20% increase in venture funding for biotech companies in 2015 compared to just 7.7% increase for software companies. Although software companies are still receiving more investments ($5.1B in the first three months of this year, compared to $1.8B for biotech companies), the business model of the drug industry has been changing, shifting its focus from in-house research and developing to outsourcing its R&D through acquisitions, partnerships, and joint ventures.